ReviewEvidence-based complementary and alternative medicine : eCAM2021
The Effects of Traditional Chinese Medicine-Associated Complementary and Alternative Medicine on Women with Polycystic Ovary Syndrome.
Review in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome.Frontiers in endocrinology · 2022Trial
- Bushen Huatan Formula Ameliorates Early Chronic Low-Grade Inflammation in Obese PCOS Via the TLR4/NF-κB Signaling Pathway: An Integrated Network Pharmacology and Experimental Study.Immunity, inflammation and disease · 2026Article
- GraphBAN-based identification of active ingredients and key gene targets in compound Chinese herbal medicines for polycystic ovary syndrome.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dihydrotanshinone as a Natural Product-Based CYP17A1 Lyase Inhibitor for Hyperandrogenic Disorders.Biomolecules · 2026Article
- Atractylenolide III mitigates polycystic ovary syndrome by activating FDX1-mediated proliferation of ovarian granulocyte cells via PI3K/AKT/mTOR.Journal of ovarian research · 2025Article
- Bushen Huatan formula alleviates polycystic ovary syndrome in rats by activating the PI3K/Akt pathway to inhibit GSDMD-mediated pyroptosis and mitochondrial damage.Journal of ovarian research · 2025Article
- Integrative Approaches to Ovulation Induction in Polycystic Ovary Syndrome: A Narrative Review of Conventional and Complementary Therapies.Biomedicines · 2025Review
- Mechanism of Zuogui pill in the treatment of polycystic ovary syndrome based on LC-MS and proteomics.Journal of ovarian research · 2025Article
- The role of traditional Chinese medicine in modulating gut microbiota to alleviating insulin resistance in polycystic ovary syndrome.Frontiers in nutrition · 2025Review
- Food Cravings and Obesity in Women with Polycystic Ovary Syndrome: Pathophysiological and Therapeutic Considerations.Nutrients · 2024Review
- Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Bailing capsule on polycystic ovary syndrome.BMC complementary medicine and therapies · 2023Article
- Effects of natural products on polycystic ovary syndrome: From traditional medicine to modern drug discovery.Heliyon · 2023Article
- Effects of TCM on polycystic ovary syndrome and its cellular endocrine mechanism.Frontiers in endocrinology · 2023Review
- Polycystic Ovarian Syndrome: A Complex Disease with a Genetics Approach.Biomedicines · 2022Review
- Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing.International journal of molecular sciences · 2022Review
- Identification of Bioactive Compounds and Potential Mechanisms of Kuntai Capsule in the Treatment of Polycystic Ovary Syndrome by Integrating Network Pharmacology and Bioinformatics.Oxidative medicine and cellular longevity · 2022Article
- Modified Cangfu Daotan decoction ameliorates polycystic ovary syndrome with insulin resistanceFrontiers in endocrinology · 2022Article
- Obesity management in polycystic ovary syndrome: disparity in knowledge between obstetrician-gynecologists and reproductive endocrinologists in China.BMC endocrine disorders · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a touchy clinical and public health problem worldwide, which adversely affects women's health and health-related comorbidities for lifetime, and represents a tremendous burden for both the family of the patient and for society. According to the diagnostic criteria used and the population studied, the prevalence rate of PCOS is between 6% and 21%. However, current conventional modern medicines for PCOS are only moderately effective at controlling the signs and symptoms, while they are not thoroughly able to prevent complications. Therefore, many patients have turned to complementary and alternative medical (CAM) treatments. CAM use is wide spread among patients with PCOS, and more than 70% of patients use CAM at one point during their diseases. The patients' primary motivations include dissatisfaction with available medications, perceive higher risk of drug side effects and crushing health burden and economic costs, desire for symptom relief, pursuit of shortening the course of disease, and the belief that CAM therapy is in accordance with the patients' values and beliefs. At present, several CAM methods have been used in women with PCOS, which has achieved obvious effects. However, biologically plausible mechanisms of the action of traditional Chinese medicine- (TCM-) associated CAM for PCOS have not been systematically reviewed. This review briefly summarizes the current progress of the impact of herbal medicine on the outcomes of PCOS and introduces the mechanisms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.